Focus
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Focus 6:104-119, Winter 2008
© 2008 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Thase, M. E.
* Articles by Rush, A. J.
* Search for Related Content
PubMed
* Articles by Thase, M. E.
* Articles by Rush, A. J.

INFLUENTIAL PUBLICATIONS

Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report

Michael E. Thase, M.D., Edward S. Friedman, M.D., Melanie M. Biggs, Ph.D., Stephen R. Wisniewski, Ph.D., Madhukar H. Trivedi, M.D., James F. Luther, M.A., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D., Patrick J. McGrath, M.D., Diane Warden, Ph.D., George Niederehe, Ph.D., Steven D. Hollon, Ph.D., and A. John Rush, M.D.

Objectives: The authors compared the effectiveness of cognitive therapy and pharmacotherapy as second-step strategies for outpatients with major depressive disorder who had received inadequate benefit from an initial trial of citalopram. Cognitive therapy was compared with medication augmentation and switch strategies. Method: An equipoise-stratified randomization strategy was used to assign participants to either augmentation of citalopram with cognitive therapy (N = 65) or medication (N = 117; either sustained-release bupropion [N = 56] or buspirone [N = 61]) or switch to cognitive therapy (N = 36) or another antidepressant (N = 86; sertraline [N = 27], sustained-release bupropion [N = 28], or extended-release venlafaxine [N = 31]). Treatment outcomes and the frequency of adverse events were compared. Results: Less than one-third of participants consented to randomization strata that permitted comparison of cognitive therapy and pharmacotherapy. Among participants who were assigned to second-step treatment, those who received cognitive therapy (either alone or in combination with citalopram) had similar response and remission rates to those assigned to medication strategies. For those who continued on citalopram, medication augmentation resulted in significantly more rapid remission than augmentation with cognitive therapy. Among those who discontinued citalopram, there were no significant differences in outcome, although those who switched to a different antidepressant reported significantly more side effects than those who received cognitive therapy alone. Conclusions: After an unsatisfactory response to citalopram, patients who consented to random assignment to either cognitive therapy or alternative pharmacologic strategies had generally comparable outcomes. Pharmacologic augmentation was more rapidly effective than cognitive therapy augmentation of citalopram, whereas switching to cognitive therapy was better tolerated than switching to a different antidepressant.

(Reprinted with permission from the American Journal of Psychiatry 2007; 164:739–752)







Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org